IVIG for refractory dysphagia in Antisynthetase syndrome: A truth hard to swallow. Issue 11 (13th November 2022)

• Record Type: Journal Article
• Authors: Alnoukari, Mais; De La Garza, Oziel Garza; Al Gburi, Karrar; Patel, Niral; Lopez, Henderson; Shamim, Muhammad; Kwang, Henry
• Is Part Of: Clinical case reports. Volume 10:Issue 11(2022)
• Page Start: n/a
• Page End: n/a
• Publication Date: 2022-11-13
• Subjects: anti‐PL‐12 antibody -- Antisynthetase syndrome -- case report -- dysphasia -- inflammatory myopathy -- intravenous immunoglobulin; Medicine -- Periodicals; 616.09
• DOI: 10.1002/ccr3.6569
• Languages: English
• ISSNs: 2050-0904

Abstract

Abstract: Refractory dysphasia could be the main symptom of Antisynthetase syndrome (ASS). IVIG may have a major impact in the successful treatment of dysphasia in patients with ASS. In our patient with ASS, IVIG treatment was an unreplaceable treatment option, and the patient regains her ability to swallow within 2 days. Abstract : Refractory dysphasia could be the main symptom of Antisynthetase syndrome (ASS). IVIG may have a major impact in the successful treatment of dysphasia in patients with ASS. A cure can be possible within just 2 days of IVIG treatment.